vTv Therapeutics Inc. Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||||||||
| 2024 | 2023(*) | 2022(*) | |||||||||||||||
| Numerator: | |||||||||||||||||
| Net loss | $ | (22,705) | $ | (25,966) | $ | (25,073) | |||||||||||
| Less: Net loss attributable to noncontrolling interests | (4,243) | (5,716) | (5,909) | ||||||||||||||
| Net loss attributable to vTv Therapeutics Inc. | (18,462) | (20,250) | (19,164) | ||||||||||||||
| Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted | $ | (18,462) | $ | (20,250) | $ | (19,164) | |||||||||||
| Denominator: | |||||||||||||||||
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted (1) | 5,771,052 | 2,084,973 | 1,919,788 | ||||||||||||||
| Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted | $ | (3.20) | $ | (9.71) | $ | (9.98) | |||||||||||
(*) Adjusted retroactively for reverse stock split, see Note 1 | |||||||||||||||||
| (1) | The shares underlying the pre-funded warrants to purchase shares of the Company’s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the year ended December 31, 2024. | |||||||
| Year Ended December 31, | |||||||||||||||||
| 2024 | 2023(*) | 2022(*) | |||||||||||||||
Class B common stock (1) (*) | 577,349 | 577,349 | 577,349 | ||||||||||||||
Common stock options granted under the Plan (*) | 705,593 | 249,247 | 208,586 | ||||||||||||||
Common stock warrants (*) | 70,639 | 76,545 | 80,359 | ||||||||||||||
Total (*) | 1,353,581 | 903,141 | 866,294 | ||||||||||||||
(*) Adjusted retroactively for reverse stock split, see Note 1 | |||||||||||||||||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.